

Medidata Rave Update

Shauna Hillman

Alliance Fall Meeting Nov, 2014

Presentation Objectives

- To provide an update on the SAE Medidata Rave integration
- To highlight reports available within Medidata Rave to assist in data management
- To provide the strategy for transitioning legacy CALGB trials in long term follow-up to Medidata Rave



Update on the Status of the SAE Integration

- The SAE integration will be piloted in trial A071102 targeted to open in December 2014
- For trial A071102, all expedited AE reporting will occur within Medidata Rave
- If you need to report an expedited AE for example on cycle 3, and have not completed your cycle 2 data entry yet, save the Patient Status Form for cycle 2 with key data entered to get the cycle 3 folder to roll out



Example of Pt Status Form for Trial A071102

Sut Paç	oject: JMR03 ge: Patient Status: Treatment (Intervention) - Treatment 01	ļ	2	Ø		
	Cycle	1 ^	ø	Ø		
	SURVIVAL STATUS					
	Participant vital status Aliv	е	Ø	Ø		
	Date of most recent contact 1 Feb 200	0	Ø	Ø		
	Death date		ø	Ø		
	Date of last contact or death 01 Feb 200	0^	Ø	Ø		
	Cause of death?		Ø	Ø	1	
	If other cause of death, specify		Ø	Ø		
	DISEASE STATUS					
	Was disease status evaluated during this reporting period?	D	Ø	Ø		
	(If yes), date of most recent disease status evaluation		Ø	Ø		
	(If yes), has the patient developed a first unequivocal progression that has not been previously reported?		ø	Ø		
	Date of progression (or relapse)		Ø	Ø		
	PROTOCOL TREATMENT					
	Will the patient continue protocol treatment (intervention) in the subsequent cycle?	s ^	ø	Ø		
	PRO/QOL ASSESSMENT(S)					
	Did the participant complete the PRO/QOL assessment(s)? Ye	s	Ø	Ø		
	(If yes), date completed		Ø	Ø		
	CONCOMITANT MEDICATIONS					

SAE Integration

- Notice that many fields on the SAE reporting forms are derived from previously entered data.
- All derived fields will be denoted with a (derived) next to the item
- If any derived items look incorrect go to the form that the field was originally entered and correct the data at the source.



New Adverse Event Form Used for Both Routine and to Launch Expedited AE Reporting

Form Instructions ?												
* red asterisk before a field denotes a required response												
Course/Cycle # (derived)												
Reporting period end date (optional, user entered if known)												
Start date of this course/cycle (derived)												
Start date of first course/cycle (derived)												
Verbatim Solicited term Adverse event v4.0 Adverse event crccae v4.0 Adverse event crccae (first 120 characters) Adverse (grade) Adverse event (grade) Adverse event creating Adverse event creating Adverse event creating Report pot (first 20) characters) Report pot (first 120) characters) Repo	Submitter By I) (derived)											
Data Data <th< td=""><td>Data Data</td></th<>	Data Data											



Questions?



Available Reports in Rave to Assist with Data Management



Query Summary Report

Query Summary Report for A151216 - TST

29 Oct 2014

	# Open Qrs	# Answered Qrs	# Closed Qrs	# Cancelled Qrs	# Total Qrs
Stage II Testing Round 13 - World	24	0	8	0	32
Site from System	24	0	8	0	32
A151216 - TST	24	0	8	0	32



Query Detail Report

Query Details Report for A091302 - TST

Stage II Testing Round 1 - World

					\wedge									
Subject	Folder	Form	Field	Log #	Query Status	Qry Open Date	Qry Open By	Query Text	Marking Gr. Name	Qry Respon Date	Response Text	Qry Respnd ed	Qry Resolv edDate	Qry ResolvedBy
BAG2	Baseline	RECIST Measurement s: Baseline	ASSESSDT PID2857241_ V1_0	0	Open	12 Aug 2014	System	This field is required. Please complete.	Site from System					
BAG2	Baseline	Laboratory Tests and Results: Baseline	LABDONEXX PID2838523_ V1_0	1	Open	12 Aug 2014	System	This field is required. Please complete.	Site from System					
BAG2	Baseline	Laboratory Tests and Results: Baseline	LABDONEXX PID2838523_ V1_0	2	Open	12 Aug 2014	System	This field is required. Please complete.	Site from System					
BAG2	Baseline	RECIST Measurement s: Baseline	NTLESPRSNT PID2516415_ V1_0	0	Open	12 Aug 2014	System	This field is required. Please complete.	Site from System					
BAG2	Baseline	RECIST Measurement s: Baseline	TLESPRSNT PID3536672_ V1_0	0	Open	12 Aug 2014	System	This field is required. Please complete.	Site from System					
BAG2	Treatment 02: Sorafenib +	RECIST Measurement s	TLESXX PID4364_V3_ 0	1	Open	12 Aug 2014	System	At least one "Target lesion site (s)" is required. Please complete.	Site from System					
BAG2	Treatment 01: Sorafenib +	Treatment (Intervention)	TDOSEXX PID2182728_ V2_0	1	Closed	12 Aug 2014	System	Data entered is non-conformant (invalid format). Please correct.	Site from System		QueryCloseBySy stem		12 Aug 2014	System
BAG2	Treatment 03: Post treatment	Adverse Events: Other	TOXXX PID3125302_ V1_1	1	Closed	12 Aug 2014	System	This adverse event has already been reported. Please report each event	Site from System		QueryCloseBySy stem		12 Aug 2014	System

23 Oct 2014



Subject PDF Report

- Must be in Firefox to run the Subject PDF report
- If you do not want all patients or all forms for a patient, go to the site level where you can select the subject and data page (form). If selecting all, the file will be quite large
- The file will contain the complete audit trial



Subject PDF

🖻 🗍 🔂 A151	216 🎇 University of Oklahoma Health Sciences Center 📄 Subject	PDF Report - Subject PDF Report
Submit Rep	port	
		View Report Help
Report Parar	neters	
Study:	▶A151216 Prod	
Sites:	University of Oklahoma Health Sciences Center	
Subjects:	♥9100973	
-	p B	
	Name	
	9100973	
	1	
DataPage:	▼* - Subject Enrollment	
	p B	
	Instance Name - DataPage Name	
	* - Refresh Folder Display	
	V * - Subject Enrollment	
	Baseline - Institutional Contacts	
	Baseline - Screening	
	Enrollment Forms - Demography	
	Enrollment Forms - Step Information	
	Enrollment Forms - Treatment Assignment	
	Review Forms - Case Evaluation	
	Review Forms - Eligibility Review	
	1	



Subject PDF

A151216: Stage II Testing Round 13: SLH003 Folder: Baseline Form: On-Study Generated On: 22 Oct 2014 21:29:24

Cycle

DESCRIPTION OF PRIMARY DISEASE

MedDRA disease code

Non-small cell lung cancer, NOS (10029514)

Primary tumor site

Histologic type

Right upper lobe lung

0

Non-small cell lung cancer NOS

Histologic grade (differentiation)

Grade I (Well differentiated)



Subject PDF



Attachment

Subject PDF-Example of Audit Trail

A151216: Stage II Testing Round 13: SLH003 Form: Subject Enrollment Generated On: 22 Oct 2014 21:29:24

Audit	User	Time (GMT)
Patient ID		
User entered 'SLH003'	Shauna Hillman (44 Hillmans6)	48 - 17 Jul 2014 19:22:00
Enrolling Site CTEP ID	(miniarios)	
User entered 'MN026'	Shauna Hillman (44 Hillmans6)	48 - 17 Jul 2014 19:22:00
Lead Organization	(miniarios)	
User entered 'Alliance'	Shauna Hillman (44 Hillmans6)	48 - 17 Jul 2014 19:22:00
Current Site CTEP ID		
User entered 'MN026'	Shauna Hillman (4 Hillmans6)	48 - 17 Jul 2014 19:22:00



Task Summary

- Use your Task Summary to navigate to tasks such as forms that need to be entered, non-conformant data and queries that need responding to
- The Task Summary is specific to your role as a Clinical Research Professional or "Read Only Role"
- If you have a "Read Only Role", nothing will be displayed in your task summary since you have no data entry responsibilities
- The Task Summary is available at the Site or Subject level



Task Summary





Task Summary





Questions

- Update on entry of AEs grades: Medidata is testing a patch to speed up the dynamic population of grades.
 - Target completion date: Jan 2015.
 - Meanwhile, save the form then enter in edit mode for faster response time. See May 2014 meeting presentation for detail
- For Rave questions, contact the Study Specific Data Manager found on the contact page of the protocol



Transition of Long Term Follow-up for Legacy CALGB Trials from Teleform to Medidata Rave

- First trial: CALGB 140202, transition on October 31, 2014
- Future trials will be batched and transitioned quarterly
- At this time, only trials in long term follow-up are being transitioned to Rave
- All data elements and collection time points remain the same just the data collection mechanism is different (Rave versus Teleform)

Transition of Long Term Follow-up for Legacy CALGB Trials from Teleform to Medidata Rave

- Next five trials to transition
 - 10404
 - 50303
 - 50604
 - 40603
 - 10801
- Communications go out to study personnel 1 month, and 1 week prior to transition



Transition of Long Term Follow-up for Legacy CALGB Trials from Teleform to Medidata Rave

- The "Patient Status: Transition to Rave" form located in the "Summary of Teleform Data" folder
 - will summarize the current patient status at the time of the Rave transition
 - will be present for all patients even patients that no longer need follow-up
 - is a "read only" form
- If there are any questions about the data displayed on this form contact the Study Data Manager

Transition of Teleform to Rave

- Follow-up status can be determined by reviewing the "Initial Follow-up in Rave" Section on the Patient Status: Transition to Rave Form
- This field will be derived for you
 - Example 1



Questions?

